Guy's and St Thomas' NHS Foundation Trust

Running trials

• Not yet recruiting

  From Early Music Audiometry to Tone Audiograms

  NCT07722936· Guy's and St Thomas' NHS Foundation Trust· Source

• Not yet recruiting

  Coronary Sinus Reducer Objective Impact on SymptoMs, Ischaemia and miCrovascular Resistance in Non-obstructive Hypertrophic CardioMyopathy

  NCT07865364· Imperial College London· Source

• Not yet recruiting

  Metabolism and Nutrition in MND

  NCT07851714· Guy's and St Thomas' NHS Foundation Trust· Source

• Not yet recruiting

  Prevalence and Measurement of Delayed Gastric Emptying in Patients Receiving Extracorporeal Membrane Oxygenation

  NCT07779174· Guy's and St Thomas' NHS Foundation Trust· Source

• Not yet recruiting

  How Can the Experience of Hospital Outpatient Departments be Improved?

  NCT07818213· King's College London· Source

• Not yet recruiting

  Feasibility of Protocolised Analgosedation in ECMO

  NCT07580781· Guy's and St Thomas' NHS Foundation Trust· Source

• Not yet recruiting

  Early Prediction of Outcomes Following Optic Neuritis: Development and Acceptability of a Prognostic Tool

  NCT07704294· King's College London· Source

• Recruiting

  Mechanisms of Atrial Pathoelectrophysiology in HCM

  NCT07454135· Guy's and St Thomas' NHS Foundation Trust· Source

• Recruiting

  Controlling Hyperactive Immunity With Long-lived Lymphocytes

  NCT07473154· Phase 1/2· Quell Therapeutics Limited· Source

• Recruiting

  Coronary Artery Stents in Heart Failure With Preserved Ejection Fraction

  NCT07560436· Phase 2· King's College London· Source

• Recruiting

  PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group

  NCT07235592· Santen SAS· Source

• Recruiting

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  NCT07363694· Phase 2/3· Pfizer· Source

• Recruiting

  Study of Lesion-Specific Invasive Haemodynamic Angina Thresholds

  NCT07386418· Imperial College London· Source

• Not yet recruiting

  Modafinil For Fatigue in IBD: A Feasibility Randomised Controlled Trial

  NCT07295834· Phase 2· Imperial College London· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes

  NCT07203768· FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS· Source

• Recruiting

  Improving Sedation Practice in Critically Ill Adult Patients Using a Co-designed Sedation Protocol

  NCT07032987· Guy's and St Thomas' NHS Foundation Trust· Source

• Recruiting

  A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

  NCT06887803· Phase 1/2· iOnctura· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source

• Active, not recruiting

  A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis

  NCT07260669· Phase 2· Gesynta Pharma AB· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Pfizer· Source

• Not yet recruiting

  Mechanistic Study of Anti-Platelet Therapy in Atherosclerosis

  NCT07169513· Guy's and St Thomas' NHS Foundation Trust· Source

• Recruiting

  A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

  NCT07029828· Phase 3· Pfizer· Source

• Recruiting

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· Phase 3· Relay Therapeutics, Inc.· Source

• Not yet recruiting

  A Study Testing a New Heart Scan Method to Improve Pacemaker Treatment for Heart Failure

  NCT07084467· King's College London· Source

• Active, not recruiting

  A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

  NCT07029711· Phase 3· Pfizer· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Exelixis· Source

• Recruiting

  EURO-STIM Registry

  NCT06971796· Inspire Medical Systems, Inc.· Source

• Recruiting

  Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

  NCT06697301· Phase 2/3· Eikon Therapeutics· Source

• Recruiting

  A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  NCT06875310· Phase 3· Mirati Therapeutics Inc.· Source

• Recruiting

  A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

  NCT06843447· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  NCT06890884· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

  NCT06873945· Phase 3· Pfizer· Source

• Active, not recruiting

  Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

  NCT05093231· Phase 2· Cambridge University Hospitals NHS Foundation Trust· Source

• Recruiting

  Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET

  NCT05889312· Guy's and St Thomas' NHS Foundation Trust· Source

• Active, not recruiting

  Preventing Kidney Injury Using Carbon Dioxide as Contrast Medium in Patients With Peripheral Arterial Disease (PAD) and Chronic Kidney Disease (CKD) Having Arterial Intervention

  NCT07891988· University of Leicester· Source

• Active, not recruiting

  Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

  NCT06806293· Phase 3· AbbVie· Source

• Active, not recruiting

  A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

  NCT06812325· Phase 3· Viridian Therapeutics, Inc.· Source

• Recruiting

  A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease

  NCT07363044· Alimentiv Inc.· Source

• Recruiting

  Supported Rescue Packs Post-discharge in Chronic Obstructive Pulmonary Disease

  NCT06347536· Phase 3· Guy's and St Thomas' NHS Foundation Trust· Source

• Recruiting

  A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

  NCT06423573· Chiesi Farmaceutici S.p.A.· Source

• Recruiting

  A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT06667076· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  Closed-loop in Adults With Type 2 Diabetes

  NCT06579404· University of Cambridge· Source

• Recruiting

  Thermotherapy in Addition to SOC Palliative Radiotherapy

  NCT06659146· King's College London· Source

• Recruiting

  Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  NCT06548542· Phase 2· AbbVie· Source

• Active, not recruiting

  Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

  NCT06456346· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Robotic Inflammatory Bowel Disease Development, Learning and Efficacy Study

  NCT06579443· University Hospitals Coventry and Warwickshire NHS Trust· Source

• Recruiting

  VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

  NCT06264180· Phase 3· Replimune, Inc.· Source

• Not yet recruiting

  FIBRotic Interstitial Lung Disease With Nocturnal hypOXaemia and EXercise Induced desaTuRAtion

  NCT06416163· Guy's and St Thomas' NHS Foundation Trust· Source

Showing 50 of 110.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers6 recruiting
• Lung cancer5 recruiting
• COPD4 recruiting
• Coronary artery disease4 recruiting
• Crohn's disease4 recruiting
• Myeloproliferative neoplasms4 recruiting
• Melanoma3 recruiting
• Head and neck cancer2 recruiting
• Hearing loss2 recruiting
• Heart failure2 recruiting
• Hypertrophic cardiomyopathy2 recruiting
• Multiple myeloma2 recruiting
• Ovarian cancer2 recruiting
• Pancreatic cancer2 recruiting
• Peripheral artery disease2 recruiting
• Ulcerative colitis2 recruiting
• Alopecia areata1 recruiting
• ALS (motor neurone disease)1 recruiting
• ANCA-associated vasculitis1 recruiting
• Asthma1 recruiting
• Atrial fibrillation1 recruiting
• Bladder cancer1 recruiting
• Chronic kidney disease1 recruiting
• Colorectal cancer1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Gastroparesis1 recruiting
• Glaucoma1 recruiting
• Haemophilia1 recruiting
• High blood pressure1 recruiting
• HIV1 recruiting
• Huntington's disease1 recruiting
• Lupus (SLE)1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple sclerosis1 recruiting
• Neuroendocrine tumours1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Obstructive sleep apnoea1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Rheumatoid arthritis1 recruiting
• Sarcoidosis1 recruiting
• Sickle cell disease1 recruiting
• Stroke1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)

  NCT06940154· Phase 2· Connect Biopharm LLC· Source

• Completed

  Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)

  NCT06940141· Phase 2· Connect Biopharm LLC· Source

• Completed

  Circle Method Observational Project - Non-interventional, Retrospective, Multicenter Data Collection

  NCT05844969· Institut für Pharmakologie und Präventive Medizin· Source

• Completed

  Use of Aptar Digital Health's Respiratory Disease Management Platform for Asthma

  NCT06364527· CoheroHealth· Source

• Completed

  Support Strategies for Parents During the First Year Following Their Child's Diagnosis of Sickle Cell Disorder

  NCT06251843· King's College London· Source

• Completed

  Personalised Cancer Care and Support: Identifying What Good Looks Like

  NCT05702684· King's College London· Source

• Completed

  AI Assisted Reader Evaluation in Acute Computed Tomography (CT) Head Interpretation

  NCT06018545· Oxford University Hospitals NHS Trust· Source

• Terminated

  A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

  NCT05678257· Phase 2· NuCana plc· Source

• Terminated

  NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

  NCT05714553· Phase 1/2· NuCana plc· Source

• Terminated

  A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients

  NCT06025110· Phase 2· ITB-Med LLC· Source

• Completed

  A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

  NCT05583526· Phase 3· Pfizer· Source

• Completed

  Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

  NCT05483933· Phase 1· Shattuck Labs, Inc.· Source

• Completed

  Virtual Peer-to-peer Support Programme for Carers of MND

  NCT04695210· King's College London· Source

• Completed

  Remote Monitoring to Improve Low Adherence in Non-invasive Ventilation

  NCT04884165· Guy's and St Thomas' NHS Foundation Trust· Source

• Completed

  A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

  NCT05002127· Phase 2/3· ALX Oncology Inc.· Source

• Completed

  Realistic Computational Electrophysiology Simulations for the Targetted Treatment of Atrial Fibrillation

  NCT05057507· University of Edinburgh· Source

• Completed

  A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

  NCT05014412· Phase 2· Pfizer· Source

• Completed

  Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

  NCT04776148· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

  NCT04870333· Phase 2/3· Cambridge University Hospitals NHS Foundation Trust· Source

• Completed

  Multi-Centre Study on the Performance of the Ponto BHX Implant System (in Adult Patients)

  NCT04310202· Oticon Medical· Source

• Terminated

  Hydroxychloroquine in ANCA Vasculitis Evaluation

  NCT04316494· Phase 4· Guy's and St Thomas' NHS Foundation Trust· Source

• Completed

  Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

  NCT04362072· Phase 4· Pfizer· Source

• Completed

  A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

  NCT04083235· Phase 3· Ipsen· Source

• Completed

  Percutaneous Deep Vein Arterialization Post-Market Study

  NCT03807661· LimFlow SA· Source

• Terminated

  Open-Label Extension of Voxelotor

  NCT04188509· Phase 3· Pfizer· Source

• Completed

  Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative Treatment for Cervical Intra-epithelial Neoplasia

  NCT03979014· Phase 3· Imperial College London· Source

• Completed

  Ustekinumab Real World Evidence Study

  NCT07748338· University Hospital Southampton NHS Foundation Trust· Source

• Completed

  Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

  NCT03569293· Phase 3· AbbVie· Source

• Completed

  A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

  NCT03587116· Phase 3· Pfizer· Source

• Completed

  Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

  NCT03517449· Phase 3· Eisai Inc.· Source

• Completed

  A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934· Phase 3· pharmaand GmbH· Source

• Completed

  Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.

  NCT02461888· Phase 2· University of Leeds· Source

• Completed

  Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer

  NCT02308072· Phase 1· University College, London· Source

• Completed

  A Study of TAS-120 in Patients With Advanced Solid Tumors

  NCT02052778· Phase 1/2· Taiho Oncology, Inc.· Source

• Recruiting

  Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)

  NCT00198068· Hospital for Special Surgery, New York· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Heart failure132 works · 2 trials
• Asthma73 works · 3 trials
• Congenital heart disease54 works · 0 trials
• Atrial fibrillation50 works · 2 trials
• Psoriasis46 works · 0 trials
• Chronic kidney disease44 works · 2 trials
• Atopic dermatitis (eczema)42 works · 2 trials
• Myeloproliferative neoplasms40 works · 8 trials
• Ulcerative colitis36 works · 4 trials
• Crohn's disease35 works · 5 trials
• Cystic fibrosis35 works · 0 trials
• COPD29 works · 6 trials
• Coronary artery disease28 works · 6 trials
• Type 1 diabetes27 works · 1 trial
• Hypertrophic cardiomyopathy23 works · 2 trials
• Idiopathic pulmonary fibrosis19 works · 0 trials
• Endometrial cancer18 works · 3 trials
• Dilated cardiomyopathy17 works · 0 trials
• Bronchiectasis17 works · 0 trials
• Ventricular tachycardia17 works · 0 trials
• Migraine16 works · 1 trial
• Aortic stenosis14 works · 1 trial
• Sarcoidosis13 works · 1 trial
• Head and neck cancer11 works · 8 trials
• Psoriatic arthritis11 works · 0 trials
• Myocarditis11 works · 0 trials
• Dystonia10 works · 0 trials
• Sickle cell disease10 works · 4 trials
• Cerebral palsy8 works · 0 trials
• Fibromyalgia8 works · 0 trials